This website uses cookies and similar technologies (hereinafter collectively referred to as ‘cookies’). We may use cookies for the following purposes:
With the buttons below, you can choose which cookies you wish to accept. On our cookie statement page, you can manage your cookie preferences. You can always withdraw your consent for cookies by making different choices there. For more information about cookies, please refer to our cookie statement.
Prof. Vareska van der Vrande, Dr Patricia Klopf, and the Research Software Engineering and Consulting (RSEC) team at RSM are listed as funders for this article on pharmaceutical firms' resource allocation decision toward lobbying and other non-market activities, and their their new drug launches.
The research is published in an Elsevier publication Research Policy, 2024;53(2).
Information for this cutting came from https://www.newsrx.com/NewsRxWebsite/